Aisa Pharma Inc.
Aisa Pharma is a late-stage, clinical development company dedicated to bringing new treatments to patients with severe autoimmune and vascular diseases, focusing on repurposing existing drugs like calcium channel blockers to treat rare diseases such as Systemic Sclerosis and Raynaud’s Phenomenon. The company is engaged in clinical trials and has received FDA orphan drug designation for its lead drug candidate, AISA-021.
Industries
Nr. of Employees
small (1-50)
Aisa Pharma Inc.
33 Brimmer Street, Suite C, Boston, MA 02108
Products
Repurposed oral cilnidipine candidate for systemic sclerosis and secondary Raynaud’s
An oral, once-daily cilnidipine-based small-molecule candidate being developed to treat secondary Raynaud’s in patients with systemic sclerosis; being evaluated alone and in combination with a PDE5 inhibitor.
Repurposed oral cilnidipine candidate for systemic sclerosis and secondary Raynaud’s
An oral, once-daily cilnidipine-based small-molecule candidate being developed to treat secondary Raynaud’s in patients with systemic sclerosis; being evaluated alone and in combination with a PDE5 inhibitor.
Services
Management and execution of clinical development activities for an internal small-molecule candidate, including trial design, site selection, enrollment oversight, and DSMB coordination.
Conduct and coordination of preclinical studies including pharmacology, abuse-potential assessment, and pharmacokinetic profiling.
Preparation for and engagement with regulatory authorities to obtain orphan designation and plan for IND/NDA filings and related incentives.
Management and execution of clinical development activities for an internal small-molecule candidate, including trial design, site selection, enrollment oversight, and DSMB coordination.
Conduct and coordination of preclinical studies including pharmacology, abuse-potential assessment, and pharmacokinetic profiling.
Preparation for and engagement with regulatory authorities to obtain orphan designation and plan for IND/NDA filings and related incentives.
Expertise Areas
- Clinical trial management
- Drug repurposing for small molecules
- Orphan drug regulatory strategy
- Preclinical pharmacology and PK
Key Technologies
- Ion channel-targeting small molecules (calcium channel modulation)
- PDE5 inhibition
- Oral small-molecule therapeutics
- Randomized double-blind crossover trial design
News & Updates
Company also provides updates on its Phase 2 RECONNOITER Study in Raynaud’s Phenomenon and Systemic Sclerosis and other corporate activities.
Phase 2 Data at EULAR AISA-021 Treatment Might Influence Systemic Sclerosis (SSc) Disease Severity.
AISA-021 impact on key Nav 1.7 pain channel to be presented at AAN. Initial positive Phase 2 data from RECONNOITER-1 Trial in Systemic Sclerosis patients with Raynaud’s Phenomenon to be presented at EULAR.
The NIH has awarded the Preclinical Screening Pain Platform (PSPP) award to Aisa’s AISA-021, a calcium-channel antagonist, for pain research.
The Data Safety Monitoring Board (DSMB) reviewed the Phase 2 data and recommended moving forward with regulatory applications.
Enrollment has begun in a Phase 2 trial evaluating AISA-021 for Raynaud’s and Scleroderma.
Company also provides updates on its Phase 2 RECONNOITER Study in Raynaud’s Phenomenon and Systemic Sclerosis and other corporate activities.
Phase 2 Data at EULAR AISA-021 Treatment Might Influence Systemic Sclerosis (SSc) Disease Severity.
AISA-021 impact on key Nav 1.7 pain channel to be presented at AAN. Initial positive Phase 2 data from RECONNOITER-1 Trial in Systemic Sclerosis patients with Raynaud’s Phenomenon to be presented at EULAR.
The NIH has awarded the Preclinical Screening Pain Platform (PSPP) award to Aisa’s AISA-021, a calcium-channel antagonist, for pain research.
The Data Safety Monitoring Board (DSMB) reviewed the Phase 2 data and recommended moving forward with regulatory applications.
Enrollment has begun in a Phase 2 trial evaluating AISA-021 for Raynaud’s and Scleroderma.